Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL613088 Target Snapshot

Mycolicibacterium smegmatis · ORGANISM · Mycolicibacterium smegmatis

Back to Search Search this target Browse approvals Evidence Card
5,051Compounds
1,262Assays
21Approved Drugs
436.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-15

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-15
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mycolicibacterium smegmatis as ChEMBL target CHEMBL613088. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mycolicibacterium smegmatis
ORGANISM · Mycolicibacterium smegmatis
As of 2026-09-15
ChEMBL target ID
CHEMBL613088
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-15
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-15
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mycolicibacterium smegmatis still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMycolicibacterium smegmatis
Target TypeORGANISM
OrganismMycolicibacterium smegmatis
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMycolicibacterium smegmatis
UniProt AccessionN/A

Mycolicibacterium smegmatis

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Mycolicibacterium smegmatis.

Review nameMycolicibacterium smegmatis
OrganismMycolicibacterium smegmatis
Clinical Profile

Clinical Phase Distribution

21
Approved
2
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50393.0
EC5043.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL376488 9.0 IC50 1.0 Approved
CHEMBL5279392 7.97 IC50 10.7 Preclinical
CHEMBL4859151 6.7 EC50 200.0 Preclinical
CHEMBL3261890 6.52 IC50 300.0 Preclinical
CHEMBL1440 6.48 IC50 330.0 Approved
CHEMBL372795 6.32 IC50 480.0 Approved
CHEMBL3261880 6.3 IC50 500.0 Preclinical
CHEMBL3261884 6.3 IC50 500.0 Preclinical
CHEMBL3817907 6.3 IC50 500.0 Preclinical
CHEMBL62382 6.22 IC50 600.0 Preclinical
Distribution

pChEMBL Value Distribution

102
5.0
48
5.5
12
6.0
4
6.5
0
7.0
1
7.5
0
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

BEDAQUILINE
CHEMBL376488
Approved 2012
Properties Compare Identifier
DOXYCYCLINE
CHEMBL1200699
Approved 1967
Properties Compare Identifier
TETRACYCLINE
CHEMBL1440
Approved 1953
Properties Compare Identifier
STREPTOMYCIN
CHEMBL372795
Approved 1946
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,263
Total Assays
160
Tested Compounds
2
Assay Types
Functional — 1,258 assays, 160 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1,124 159 5.0
assay format 110 1 5.8
cell-based format 24 0 —
ADME — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 4 0 —
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine